je.st
news
Tag: accepts
Polycom accepts USD 2 bln bid from Siris
2016-07-08 15:29:00| Telecompaper Headlines
(Telecompaper) Polycom said it has terminated its previously announced USD 1.96 billion merger agreement with Canada's Mitel Networks and accepted one from Siris, for USD 12.50 per share in cash, or a total of USD 2 billion, including debt. A report had earlier noted the company received a higher offer from an unidentified private equity firm. Polycom will pay the requisite termination fee and then enter into a new merger agreement with Siris, previously described as "Sponsor 1" in Polycom's filings with the US Securities and Exchange Commission.
Priorclave Voluntarily Accepts London Living Wage
2016-07-07 10:49:00| Food Processing Technology
To attract skilled workers, Priorclave has agreed to implement the London Living Wage.
Tags: living
london
accepts
wage
FERC Accepts Measures Addressing Gas-Electric Reliability in Southern California
2016-06-08 17:16:00| Transmission & Distribution World
The Federal Energy Regulatory Commission has accepted interim measures to address the limited operability of the Aliso Canyon natural gas storage facility read more
Tags: california
southern
measures
accepts
Patties Foods accepts $232m acquisition bid from Pacific Equity Partners
2016-06-03 01:00:00| Food Processing Technology
Australia-based Patties Foods has agreed to an acquisition bid of approximately $232m from Pacific Equity Partners (PEP).
Tags: partners
bid
pacific
equity
Merck Announces FDA Accepts Samsung Bioepis Biologics License Application (BLA) for SB2 (Infliximab), an Investigational Biosimilar of Remicade
2016-05-24 01:50:08| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. First BLA Filed by Samsung Bioepis as Part of Its Partnership with Merck KENILWORTH, N.J. Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) submitted by Samsung Bioepis Co., Ltd. for SB2 (infliximab), an investigational biosimilar candidate of Remicade. Language: English read more
Tags: of
application
license
samsung
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] next »